CLASS III ONGOING Drug recall · Reported 6 May 2026 · FDA Enforcement Report

Lidocaine Wound Gel (Benzalkonium Chloride recalled

Water-Jel Technologies is recalling Lidocaine Wound Gel (Benzalkonium Chloride, 0.13% and Lidocaine Hydrochloride, 2%), distributed nationwide in the US. The recall was initiated on 7 Apr 2026 and the FDA has classified it as Class III.

Check your package

Lot, batch or date codesLots: A5014, A5018, A5019
Quantity recalled31,488 tubes

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0509-2026
FDA event ID
98737
Recalling firm
Water-Jel Technologies, Huntersville, NC
Classification
Class III
Status
Ongoing
Recall initiated
7 Apr 2026
FDA classified
30 Apr 2026
Reported
6 May 2026
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Other Reasons
Drug class
Pain Medication

Timeline

7 Apr 2026Recall initiated by company
30 Apr 2026Classified by FDA+23 days
6 May 2026Published in enforcement report+6 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Failed PH Specifications

Product as listed by the FDA

Lidocaine Wound Gel (Benzalkonium Chloride, 0.13% and Lidocaine Hydrochloride, 2%), NET WT 0.5 OZ (14 g), Distributed by: CVS PHarmacy, INc., One CVS Drive, Woonsocket, RI 02895. NDC 59898-950

Where it was distributed

Nationwide in the USA

Nationwide

Stores named: CVS

Questions about this recall

Why was it recalled?

Failed PH Specifications

Which lots are affected?

Lots: A5014, A5018, A5019

Where was it sold?

Nationwide in the USA

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class III mean?

Class III recalls are for products unlikely to cause any adverse health consequence, usually labelling or quality issues.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.